Your browser doesn't support javascript.
loading
Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10-year experience in a single center.
Echeverría, Luis E; Figueredo, Antonio; Rodriguez, María J; Salazar, Leonardo; Pizarro, Camilo; Morillo, Carlos A; Rojas, Lyda Z; Gómez-Ochoa, Sergio A; Castillo, Victor R.
Afiliação
  • Echeverría LE; Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Figueredo A; Advanced Heart Failure Group, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Rodriguez MJ; Advanced Heart Failure Group, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Salazar L; Cardiovascular Surgery, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Pizarro C; Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Morillo CA; Advanced Heart Failure Group, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Rojas LZ; Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Support Program, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Gómez-Ochoa SA; Advanced Heart Failure Group, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Castillo VR; Adult Intensive Care Unit, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
Transpl Infect Dis ; 23(4): e13549, 2021 Aug.
Article em En | MEDLINE | ID: mdl-33345420
BACKGROUND: Heart transplant (HT) remains the most frequently indicated therapy for patients with end-stage heart failure that improves prognosis in Chagas cardiomyopathy (CCM). However, the lack of benznidazole therapy and availability of RT-PCR follow-up in many centers is a major limitation to perform this life-saving intervention, as there are concerns related with the risk of reactivation. We aimed to describe the outcomes of a cohort of patients with CCM who underwent HT using a conventional protocol with mycophenolate mofetil, without benznidazole prophylaxis or RT-PCR follow-up. METHODS: Retrospective cohort study. Between 2008 and 2018, 43 patients with CCM underwent HT. A descriptive analysis to characterize outcomes as rejection, infectious and neoplastic complications and a survival analysis was carried out. RESULTS: Median of follow-up was 4.3 (IR 4.28) years. Survival at 1 month, 1 year, and 5 years was 95%, 85%, and 75%, respectively, infections being the main cause of death (60%). Reactivations occurred in only three patients (7.34%) and were not related to mortality. CONCLUSION: This cohort showed a favorable survival and a low reactivation rate without an impact on mortality. Our results suggest that performing HT in patients with CCM following conventional guidelines and recommendations for other etiologies is a safe approach.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomiopatia Chagásica / Transplante de Coração / Insuficiência Cardíaca Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Transpl Infect Dis Assunto da revista: TRANSPLANTE Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Dinamarca
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomiopatia Chagásica / Transplante de Coração / Insuficiência Cardíaca Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Transpl Infect Dis Assunto da revista: TRANSPLANTE Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Dinamarca